More on SGP
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $26.16 |
|
|||
| Open | $26.52 | ||||
| 52 Wk High | $29.75 | ||||
| 52 Wk Low | $15.27 | ||||
| Day High | $27.73 | ||||
| Day Low | $26.04 | ||||
| P/E | 18.35 | ||||
| EPS | $1.51 | ||||
| Volume | 86,126 | ||||
- H.C. Wainwright Reiterates Buy Rating on SpyGlass Pharma (SGP)
- Form 8-K SpyGlass Pharma, Inc. For: Oct 19
- SpyGlass Pharma reports 4-year glaucoma implant trial data
- SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System
- H.C. Wainwright Reiterates Buy Rating on SpyGlass Pharma (SGP)
- SpyGlass Pharma (SGP) Reiterated at Buy by Stifel as AVS Acquisition Announced
- Form 8-K SpyGlass Pharma, Inc. For: Oct 01
- SpyGlass Pharma buys AVS from Santen for $13 million
- SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
Entities mentioned with SGP
- Citi | View Related Stories »
- JPMorgan | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- UBS | View Related Stories »
- Jefferies & Co | View Related Stories »
- FDA | View Related Stories »
- Show More...
